Abstract 1980
Background
Necrotizing fasciitis (NF) is a live-treating acute skin infection of soft tissues and muscles, extended from a trivial skin lesion, with rapid progression to necrosis. It is relatively uncommon and has a high mortality rate (∼32.2%) approaching 100% without treatment. Most cases present an anaerobic bacterium that produce gas, accumulated in the soft tissue spaces giving the characteristic image of gas gangrene on X rays (1). Site inspection reveals inflammation, oedema, and discoloration or gangrene and anaesthesia. A distinguishing clinical feature is the induration of the subcutaneous tissues (2). Early diagnosis is mandatory. Delay is associated with more extensive surgery and higher rates of amputation and mortality (1). Therapy includes radical surgical debridement with empirical broad-spectrum antibiotic coverage (2,3). Immunosuppressed patients or suffering from haematological malignancies are particularly at risk presenting an atypical etiopathology (3).
Methods
Two cases were retrospectively reviewed through medical history records to determine possible nursing implications to prevent or detect earlier cases in the future.
Results
Patient A: 53 year old woman being treated for Acute Myeloid Leukaemia (AML) with grade 4 neutropenia. She referred pain in her catheter site and presented fever and hypotension. After some days NF was diagnosed requiring 3 surgical interventions. Pseudomonas Aeruginosa was isolated in blood cultures. Patient B: 71 year old woman under treatment for AML with grade 3 neutropenia. NF in her Peripheral Insertion Central Catheter site was diagnosed. She presented no symthoms the days before but fever in the diagnosis. She required 2 surgical interventions. Klebsiella oxytoca and Enterobacter cloacae were isolated in blood cultures. Intensive care admission and longer hospitalization was required in both cases. NF was controlled but they had long term consequences (loss of mobility, paresthesia or pain).
Conclusions
FN is a rare potentially lethal infection in neutropenic patients. Oncology Nurses must be aware of this complication and patient implications in order to detect it earlier. Prompt diagnosis is crucial to prevent major surgical trauma, mortality and long-term morbidity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hosptial Clínic de Barcelona.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract